Chorionic Gonadotropin NDC 63323-030

NDC codes

FDA NDC Directory

Product NDC (as listed)63323-030Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63323-0030Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63323-030-11	63323003011	1 KIT in 1 CARTON (63323-030-11) * 10 mL in 1 VIAL, MULTI-DOSE * 10 mL in 1 VIAL, MULTI-DOSEMarketed from Apr 21, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Chorionic Gonadotropin
Generic name (nonproprietary): chorionic gonadotropin
Dosage form: Kit
Labeler: Fresenius Kabi USA, LLC
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 017067
Marketing start: Apr 21, 2011
Listing expires: Dec 31, 2026
Identifiers: Product ID 63323-030_386cd061-6485-428c-aec1-a4f58d90d339SPL ID 386cd061-6485-428c-aec1-a4f58d90d339SPL set ID f93b2baa-03ac-4650-b35a-20b818d712d6RxCUI 896854UPC 0363323030100, 0363323950019, 0363323030117

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N463323003011 followed by a unit qualifier and the quantity

Package 63323-0030-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 11, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE: HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ‘‘NORMAL’’ DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. 1. Prepubertal cryptorchidism not due to anatomical obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG admini…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 017067

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 017067
Product	Strength	Form · route	Labeler	Product NDC
Chorionic Gonadotropin	—	Kit	NuCare Pharmaceuticals,Inc.	68071-3815